methyl 2-(3'-hydroxy-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenylcarbonyl)pyridine-5-carboxylate | 758690-06-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 2-(3'-hydroxy-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenylcarbonyl)pyridine-5-carboxylate
• 英文别名: Methyl 6-(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)pyridine-3-carboxylate
• CAS: 758690-06-1
• 化学式: C₂₂H₂₅NO₄
• 分子量: 367.445
• InChiKey: HFJLORPCQZGTPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  溴丙烷 、 methyl 2-(3'-hydroxy-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenylcarbonyl)pyridine-5-carboxylate 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以84%的产率得到methyl 2-(3'-n-propoxy-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenylcarbonyl)-5-pyridinecarboxylate
  参考文献：
  名称：

  Determinants of Retinoid X Receptor Transcriptional Antagonism

  摘要：

  The synthesis and bloactivity of the retinoid X receptor (RXR) antagonist 4-[(3'-n-butyl-5',6', 7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenyl)(cyclopropylidene)methyl]benzoic acid and several heteroatom-substituted analogues are described. Ligand design was based on the scaffold of the X-methyl RXR-selective agonist analogue and reports that 3'-n-propyl and longer n-alkyl groups conferred RXR antagonism. The transcriptional antagonism of the 3'-n-butyl analogue was demonstrated by its blockade of retinoic acid receptor (RAR) beta expression induced by the RXRalpha/peroxisome proliferator-activated receptor (PPAR) gamma heterodimer complexed with an RXRalpha agonist plus the PPARgamma agonist ciglitazone and the inhibition of 9-cis-RA-induced coactivator SRC-1a recruitment to RXRalpha. Receptor-ligand docking studies using full-atom flexible ligand and flexible receptor suggested that binding of the antagonist to the RXRa antagonist conformation was favored because the salt bridge that formed between the retinoid carboxylate and the RXRalpha helix H5 arginine-321 was far stronger than that formed on its binding to the agonist conformation. The antagonist also blocked activation of RAR subtypes alpha and beta by 9-cis-RA but not that of RARgamma.

  DOI：

  10.1021/jm030651g
• 作为产物：
  描述：

  5-(甲氧羰基)-2-吡啶羧酸 在 三氯化铝 、 草酰氯 作用下， 以 苯 为溶剂， 反应 3.5h， 生成 methyl 2-(3'-hydroxy-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenylcarbonyl)pyridine-5-carboxylate
  参考文献：
  名称：

  Determinants of Retinoid X Receptor Transcriptional Antagonism

  摘要：

  The synthesis and bloactivity of the retinoid X receptor (RXR) antagonist 4-[(3'-n-butyl-5',6', 7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenyl)(cyclopropylidene)methyl]benzoic acid and several heteroatom-substituted analogues are described. Ligand design was based on the scaffold of the X-methyl RXR-selective agonist analogue and reports that 3'-n-propyl and longer n-alkyl groups conferred RXR antagonism. The transcriptional antagonism of the 3'-n-butyl analogue was demonstrated by its blockade of retinoic acid receptor (RAR) beta expression induced by the RXRalpha/peroxisome proliferator-activated receptor (PPAR) gamma heterodimer complexed with an RXRalpha agonist plus the PPARgamma agonist ciglitazone and the inhibition of 9-cis-RA-induced coactivator SRC-1a recruitment to RXRalpha. Receptor-ligand docking studies using full-atom flexible ligand and flexible receptor suggested that binding of the antagonist to the RXRa antagonist conformation was favored because the salt bridge that formed between the retinoid carboxylate and the RXRalpha helix H5 arginine-321 was far stronger than that formed on its binding to the agonist conformation. The antagonist also blocked activation of RAR subtypes alpha and beta by 9-cis-RA but not that of RARgamma.

  DOI：

  10.1021/jm030651g

文献信息

• Determinants of Retinoid X Receptor Transcriptional Antagonism
  作者：Claudio N. Cavasotto、Gang Liu、Sharon Y. James、Peter D. Hobbs、Valerie J. Peterson、Ananyo A. Bhattacharya、Siva K. Kolluri、Xiao-kun Zhang、Mark Leid、Ruben Abagyan、Robert C. Liddington、Marcia I. Dawson

  DOI：10.1021/jm030651g

  日期：2004.8.1

  The synthesis and bloactivity of the retinoid X receptor (RXR) antagonist 4-[(3'-n-butyl-5',6', 7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenyl)(cyclopropylidene)methyl]benzoic acid and several heteroatom-substituted analogues are described. Ligand design was based on the scaffold of the X-methyl RXR-selective agonist analogue and reports that 3'-n-propyl and longer n-alkyl groups conferred RXR antagonism. The transcriptional antagonism of the 3'-n-butyl analogue was demonstrated by its blockade of retinoic acid receptor (RAR) beta expression induced by the RXRalpha/peroxisome proliferator-activated receptor (PPAR) gamma heterodimer complexed with an RXRalpha agonist plus the PPARgamma agonist ciglitazone and the inhibition of 9-cis-RA-induced coactivator SRC-1a recruitment to RXRalpha. Receptor-ligand docking studies using full-atom flexible ligand and flexible receptor suggested that binding of the antagonist to the RXRa antagonist conformation was favored because the salt bridge that formed between the retinoid carboxylate and the RXRalpha helix H5 arginine-321 was far stronger than that formed on its binding to the agonist conformation. The antagonist also blocked activation of RAR subtypes alpha and beta by 9-cis-RA but not that of RARgamma.